Ani Pharmaceuticals ((ANIP)) has held its Q1 earnings call. Read on for the main highlights of the call.
ANI Pharmaceuticals’ recent earnings call reflected a positive sentiment, highlighting the company’s strong growth trajectory. The call underscored record revenue achievements and an optimistic outlook for the future, driven by robust performance in the generics and Cortrophin Gel segments. Despite facing challenges with market access and salesforce turnover affecting retina products, the company is proactively addressing these issues through strategic investments and operational adjustments.
Record Revenue and Growth
ANI Pharmaceuticals reported a record revenue of $197.1 million for the first quarter of 2025, marking a 43% year-over-year increase on an as-reported basis and 32% on an organic basis. This impressive growth was fueled by exceptional performance in the generics, Cortrophin Gel, and brands portfolio segments.
Increased 2025 Guidance
In light of the strong performance in the first quarter, ANI Pharmaceuticals has raised its 2025 revenue guidance to a range of $768 million to $793 million, indicating a growth of 25% to 29% over the previous year.
Cortrophin Gel Growth
Cortrophin Gel was a standout performer, generating $52.9 million in revenue for Q1, a 43% increase from the same period in 2024. The company anticipates Cortrophin Gel revenues to rise by 34% to 38% for the entire year.
Generics Business Performance
The generics segment delivered strong results with Q1 revenue of $98.7 million, representing a 41% increase over Q1 2024. This growth was driven by successful new product launches and robust base business execution.
Strategic Investments and New Approvals
ANI Pharmaceuticals made strategic moves, including the buyout of the royalty obligation on ILUVIEN and YUTIQ, and launched a pre-filled syringe for Cortrophin Gel, which has received positive feedback.
Challenges with Retina Products
Revenues from ILUVIEN and YUTIQ were $16.1 million in Q1, impacted by market access challenges for Medicare patients and turnover in the US ophthalmology sales force.
Medicare Access Issues
The first quarter saw reduced access for Medicare patients due to insufficient funding for patient support foundations, impacting products reimbursed under Medicare Part B.
Salesforce Turnover
Turnover in the US Ophthalmology Salesforce affected performance, but the company is actively working to strengthen the team with new hires.
Forward-Looking Guidance
ANI Pharmaceuticals has provided an optimistic forward-looking guidance based on its Q1 success and favorable demand trends. The company raised its 2025 revenue guidance to $768 million to $793 million, reflecting a 25% to 29% growth over 2024. Adjusted non-GAAP EBITDA is anticipated to range from $195 million to $205 million, up 25% to 31% from the previous year. The generics business is expected to experience mid-double-digit growth throughout the year.
In conclusion, ANI Pharmaceuticals’ earnings call conveyed a strong positive sentiment, highlighting record revenue growth and an optimistic outlook for 2025. The company’s strategic investments and operational adjustments aim to address current challenges, positioning ANI for continued success in the coming quarters.